NCT01913990 - Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. | Biotech Hunter

Enrollment

323

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions

Emesis

Interventions

DRUG

Dexamethasone, Ondansetron, Aprepitant

Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.

OTHER

Arm A: Standard Anti-emetic regimen

Treating physician's discretion for type of anti-emetic to be prescribed.

Trial Locations (1)

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa